Pharma & Healthcare
Global Recombinant Vaccines Market Research Report 2025
- Sep 09, 25
- ID: 497001
- Pages: 87
- Figures: 81
- Views: 5
This report aims to provide a comprehensive presentation of the global market for Recombinant Vaccines, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Vaccines.
The Recombinant Vaccines market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Recombinant Vaccines market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Recombinant Vaccines companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck & Co., Inc
Green Cross Corporation
Pfizer Inc.
Bayer AG
Sanofi S A.
Protein Science Corporation
GlaxoSmithKline Plc.
Novartis AG
Bharat Biotech
AstraZeneca Plc.
Johnson & Johnson
Emergent BioSolutions Inc
Novavax, Inc
Serum Institute of India Pvt. Ltd
Dynavax Technologies Corporation
Segment by Type
Subunit Recombinant Vaccines
Attenuated Recombinant Vaccines
Vector Recombinant Vaccines
Segment by Application
Recombinant Human Vaccines
Animal Recombinant Vaccines
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Recombinant Vaccines company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The Recombinant Vaccines market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Recombinant Vaccines market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Recombinant Vaccines companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck & Co., Inc
Green Cross Corporation
Pfizer Inc.
Bayer AG
Sanofi S A.
Protein Science Corporation
GlaxoSmithKline Plc.
Novartis AG
Bharat Biotech
AstraZeneca Plc.
Johnson & Johnson
Emergent BioSolutions Inc
Novavax, Inc
Serum Institute of India Pvt. Ltd
Dynavax Technologies Corporation
Segment by Type
Subunit Recombinant Vaccines
Attenuated Recombinant Vaccines
Vector Recombinant Vaccines
Segment by Application
Recombinant Human Vaccines
Animal Recombinant Vaccines
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Recombinant Vaccines company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Recombinant Vaccines Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Subunit Recombinant Vaccines
1.2.3 Attenuated Recombinant Vaccines
1.2.4 Vector Recombinant Vaccines
1.3 Market by Application
1.3.1 Global Recombinant Vaccines Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Recombinant Human Vaccines
1.3.3 Animal Recombinant Vaccines
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Recombinant Vaccines Market Perspective (2020-2031)
2.2 Global Recombinant Vaccines Growth Trends by Region
2.2.1 Global Recombinant Vaccines Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Recombinant Vaccines Historic Market Size by Region (2020-2025)
2.2.3 Recombinant Vaccines Forecasted Market Size by Region (2026-2031)
2.3 Recombinant Vaccines Market Dynamics
2.3.1 Recombinant Vaccines Industry Trends
2.3.2 Recombinant Vaccines Market Drivers
2.3.3 Recombinant Vaccines Market Challenges
2.3.4 Recombinant Vaccines Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Recombinant Vaccines Players by Revenue
3.1.1 Global Top Recombinant Vaccines Players by Revenue (2020-2025)
3.1.2 Global Recombinant Vaccines Revenue Market Share by Players (2020-2025)
3.2 Global Recombinant Vaccines Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Recombinant Vaccines Revenue
3.4 Global Recombinant Vaccines Market Concentration Ratio
3.4.1 Global Recombinant Vaccines Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Recombinant Vaccines Revenue in 2024
3.5 Global Key Players of Recombinant Vaccines Head office and Area Served
3.6 Global Key Players of Recombinant Vaccines, Product and Application
3.7 Global Key Players of Recombinant Vaccines, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Recombinant Vaccines Breakdown Data by Type
4.1 Global Recombinant Vaccines Historic Market Size by Type (2020-2025)
4.2 Global Recombinant Vaccines Forecasted Market Size by Type (2026-2031)
5 Recombinant Vaccines Breakdown Data by Application
5.1 Global Recombinant Vaccines Historic Market Size by Application (2020-2025)
5.2 Global Recombinant Vaccines Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Recombinant Vaccines Market Size (2020-2031)
6.2 North America Recombinant Vaccines Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Recombinant Vaccines Market Size by Country (2020-2025)
6.4 North America Recombinant Vaccines Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Recombinant Vaccines Market Size (2020-2031)
7.2 Europe Recombinant Vaccines Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Recombinant Vaccines Market Size by Country (2020-2025)
7.4 Europe Recombinant Vaccines Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Recombinant Vaccines Market Size (2020-2031)
8.2 Asia-Pacific Recombinant Vaccines Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Recombinant Vaccines Market Size by Region (2020-2025)
8.4 Asia-Pacific Recombinant Vaccines Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Recombinant Vaccines Market Size (2020-2031)
9.2 Latin America Recombinant Vaccines Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Recombinant Vaccines Market Size by Country (2020-2025)
9.4 Latin America Recombinant Vaccines Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Recombinant Vaccines Market Size (2020-2031)
10.2 Middle East & Africa Recombinant Vaccines Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Recombinant Vaccines Market Size by Country (2020-2025)
10.4 Middle East & Africa Recombinant Vaccines Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Merck & Co., Inc
11.1.1 Merck & Co., Inc Company Details
11.1.2 Merck & Co., Inc Business Overview
11.1.3 Merck & Co., Inc Recombinant Vaccines Introduction
11.1.4 Merck & Co., Inc Revenue in Recombinant Vaccines Business (2020-2025)
11.1.5 Merck & Co., Inc Recent Development
11.2 Green Cross Corporation
11.2.1 Green Cross Corporation Company Details
11.2.2 Green Cross Corporation Business Overview
11.2.3 Green Cross Corporation Recombinant Vaccines Introduction
11.2.4 Green Cross Corporation Revenue in Recombinant Vaccines Business (2020-2025)
11.2.5 Green Cross Corporation Recent Development
11.3 Pfizer Inc.
11.3.1 Pfizer Inc. Company Details
11.3.2 Pfizer Inc. Business Overview
11.3.3 Pfizer Inc. Recombinant Vaccines Introduction
11.3.4 Pfizer Inc. Revenue in Recombinant Vaccines Business (2020-2025)
11.3.5 Pfizer Inc. Recent Development
11.4 Bayer AG
11.4.1 Bayer AG Company Details
11.4.2 Bayer AG Business Overview
11.4.3 Bayer AG Recombinant Vaccines Introduction
11.4.4 Bayer AG Revenue in Recombinant Vaccines Business (2020-2025)
11.4.5 Bayer AG Recent Development
11.5 Sanofi S A.
11.5.1 Sanofi S A. Company Details
11.5.2 Sanofi S A. Business Overview
11.5.3 Sanofi S A. Recombinant Vaccines Introduction
11.5.4 Sanofi S A. Revenue in Recombinant Vaccines Business (2020-2025)
11.5.5 Sanofi S A. Recent Development
11.6 Protein Science Corporation
11.6.1 Protein Science Corporation Company Details
11.6.2 Protein Science Corporation Business Overview
11.6.3 Protein Science Corporation Recombinant Vaccines Introduction
11.6.4 Protein Science Corporation Revenue in Recombinant Vaccines Business (2020-2025)
11.6.5 Protein Science Corporation Recent Development
11.7 GlaxoSmithKline Plc.
11.7.1 GlaxoSmithKline Plc. Company Details
11.7.2 GlaxoSmithKline Plc. Business Overview
11.7.3 GlaxoSmithKline Plc. Recombinant Vaccines Introduction
11.7.4 GlaxoSmithKline Plc. Revenue in Recombinant Vaccines Business (2020-2025)
11.7.5 GlaxoSmithKline Plc. Recent Development
11.8 Novartis AG
11.8.1 Novartis AG Company Details
11.8.2 Novartis AG Business Overview
11.8.3 Novartis AG Recombinant Vaccines Introduction
11.8.4 Novartis AG Revenue in Recombinant Vaccines Business (2020-2025)
11.8.5 Novartis AG Recent Development
11.9 Bharat Biotech
11.9.1 Bharat Biotech Company Details
11.9.2 Bharat Biotech Business Overview
11.9.3 Bharat Biotech Recombinant Vaccines Introduction
11.9.4 Bharat Biotech Revenue in Recombinant Vaccines Business (2020-2025)
11.9.5 Bharat Biotech Recent Development
11.10 AstraZeneca Plc.
11.10.1 AstraZeneca Plc. Company Details
11.10.2 AstraZeneca Plc. Business Overview
11.10.3 AstraZeneca Plc. Recombinant Vaccines Introduction
11.10.4 AstraZeneca Plc. Revenue in Recombinant Vaccines Business (2020-2025)
11.10.5 AstraZeneca Plc. Recent Development
11.11 Johnson & Johnson
11.11.1 Johnson & Johnson Company Details
11.11.2 Johnson & Johnson Business Overview
11.11.3 Johnson & Johnson Recombinant Vaccines Introduction
11.11.4 Johnson & Johnson Revenue in Recombinant Vaccines Business (2020-2025)
11.11.5 Johnson & Johnson Recent Development
11.12 Emergent BioSolutions Inc
11.12.1 Emergent BioSolutions Inc Company Details
11.12.2 Emergent BioSolutions Inc Business Overview
11.12.3 Emergent BioSolutions Inc Recombinant Vaccines Introduction
11.12.4 Emergent BioSolutions Inc Revenue in Recombinant Vaccines Business (2020-2025)
11.12.5 Emergent BioSolutions Inc Recent Development
11.13 Novavax, Inc
11.13.1 Novavax, Inc Company Details
11.13.2 Novavax, Inc Business Overview
11.13.3 Novavax, Inc Recombinant Vaccines Introduction
11.13.4 Novavax, Inc Revenue in Recombinant Vaccines Business (2020-2025)
11.13.5 Novavax, Inc Recent Development
11.14 Serum Institute of India Pvt. Ltd
11.14.1 Serum Institute of India Pvt. Ltd Company Details
11.14.2 Serum Institute of India Pvt. Ltd Business Overview
11.14.3 Serum Institute of India Pvt. Ltd Recombinant Vaccines Introduction
11.14.4 Serum Institute of India Pvt. Ltd Revenue in Recombinant Vaccines Business (2020-2025)
11.14.5 Serum Institute of India Pvt. Ltd Recent Development
11.15 Dynavax Technologies Corporation
11.15.1 Dynavax Technologies Corporation Company Details
11.15.2 Dynavax Technologies Corporation Business Overview
11.15.3 Dynavax Technologies Corporation Recombinant Vaccines Introduction
11.15.4 Dynavax Technologies Corporation Revenue in Recombinant Vaccines Business (2020-2025)
11.15.5 Dynavax Technologies Corporation Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Recombinant Vaccines Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Subunit Recombinant Vaccines
1.2.3 Attenuated Recombinant Vaccines
1.2.4 Vector Recombinant Vaccines
1.3 Market by Application
1.3.1 Global Recombinant Vaccines Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Recombinant Human Vaccines
1.3.3 Animal Recombinant Vaccines
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Recombinant Vaccines Market Perspective (2020-2031)
2.2 Global Recombinant Vaccines Growth Trends by Region
2.2.1 Global Recombinant Vaccines Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Recombinant Vaccines Historic Market Size by Region (2020-2025)
2.2.3 Recombinant Vaccines Forecasted Market Size by Region (2026-2031)
2.3 Recombinant Vaccines Market Dynamics
2.3.1 Recombinant Vaccines Industry Trends
2.3.2 Recombinant Vaccines Market Drivers
2.3.3 Recombinant Vaccines Market Challenges
2.3.4 Recombinant Vaccines Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Recombinant Vaccines Players by Revenue
3.1.1 Global Top Recombinant Vaccines Players by Revenue (2020-2025)
3.1.2 Global Recombinant Vaccines Revenue Market Share by Players (2020-2025)
3.2 Global Recombinant Vaccines Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Recombinant Vaccines Revenue
3.4 Global Recombinant Vaccines Market Concentration Ratio
3.4.1 Global Recombinant Vaccines Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Recombinant Vaccines Revenue in 2024
3.5 Global Key Players of Recombinant Vaccines Head office and Area Served
3.6 Global Key Players of Recombinant Vaccines, Product and Application
3.7 Global Key Players of Recombinant Vaccines, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Recombinant Vaccines Breakdown Data by Type
4.1 Global Recombinant Vaccines Historic Market Size by Type (2020-2025)
4.2 Global Recombinant Vaccines Forecasted Market Size by Type (2026-2031)
5 Recombinant Vaccines Breakdown Data by Application
5.1 Global Recombinant Vaccines Historic Market Size by Application (2020-2025)
5.2 Global Recombinant Vaccines Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Recombinant Vaccines Market Size (2020-2031)
6.2 North America Recombinant Vaccines Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Recombinant Vaccines Market Size by Country (2020-2025)
6.4 North America Recombinant Vaccines Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Recombinant Vaccines Market Size (2020-2031)
7.2 Europe Recombinant Vaccines Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Recombinant Vaccines Market Size by Country (2020-2025)
7.4 Europe Recombinant Vaccines Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Recombinant Vaccines Market Size (2020-2031)
8.2 Asia-Pacific Recombinant Vaccines Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Recombinant Vaccines Market Size by Region (2020-2025)
8.4 Asia-Pacific Recombinant Vaccines Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Recombinant Vaccines Market Size (2020-2031)
9.2 Latin America Recombinant Vaccines Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Recombinant Vaccines Market Size by Country (2020-2025)
9.4 Latin America Recombinant Vaccines Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Recombinant Vaccines Market Size (2020-2031)
10.2 Middle East & Africa Recombinant Vaccines Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Recombinant Vaccines Market Size by Country (2020-2025)
10.4 Middle East & Africa Recombinant Vaccines Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Merck & Co., Inc
11.1.1 Merck & Co., Inc Company Details
11.1.2 Merck & Co., Inc Business Overview
11.1.3 Merck & Co., Inc Recombinant Vaccines Introduction
11.1.4 Merck & Co., Inc Revenue in Recombinant Vaccines Business (2020-2025)
11.1.5 Merck & Co., Inc Recent Development
11.2 Green Cross Corporation
11.2.1 Green Cross Corporation Company Details
11.2.2 Green Cross Corporation Business Overview
11.2.3 Green Cross Corporation Recombinant Vaccines Introduction
11.2.4 Green Cross Corporation Revenue in Recombinant Vaccines Business (2020-2025)
11.2.5 Green Cross Corporation Recent Development
11.3 Pfizer Inc.
11.3.1 Pfizer Inc. Company Details
11.3.2 Pfizer Inc. Business Overview
11.3.3 Pfizer Inc. Recombinant Vaccines Introduction
11.3.4 Pfizer Inc. Revenue in Recombinant Vaccines Business (2020-2025)
11.3.5 Pfizer Inc. Recent Development
11.4 Bayer AG
11.4.1 Bayer AG Company Details
11.4.2 Bayer AG Business Overview
11.4.3 Bayer AG Recombinant Vaccines Introduction
11.4.4 Bayer AG Revenue in Recombinant Vaccines Business (2020-2025)
11.4.5 Bayer AG Recent Development
11.5 Sanofi S A.
11.5.1 Sanofi S A. Company Details
11.5.2 Sanofi S A. Business Overview
11.5.3 Sanofi S A. Recombinant Vaccines Introduction
11.5.4 Sanofi S A. Revenue in Recombinant Vaccines Business (2020-2025)
11.5.5 Sanofi S A. Recent Development
11.6 Protein Science Corporation
11.6.1 Protein Science Corporation Company Details
11.6.2 Protein Science Corporation Business Overview
11.6.3 Protein Science Corporation Recombinant Vaccines Introduction
11.6.4 Protein Science Corporation Revenue in Recombinant Vaccines Business (2020-2025)
11.6.5 Protein Science Corporation Recent Development
11.7 GlaxoSmithKline Plc.
11.7.1 GlaxoSmithKline Plc. Company Details
11.7.2 GlaxoSmithKline Plc. Business Overview
11.7.3 GlaxoSmithKline Plc. Recombinant Vaccines Introduction
11.7.4 GlaxoSmithKline Plc. Revenue in Recombinant Vaccines Business (2020-2025)
11.7.5 GlaxoSmithKline Plc. Recent Development
11.8 Novartis AG
11.8.1 Novartis AG Company Details
11.8.2 Novartis AG Business Overview
11.8.3 Novartis AG Recombinant Vaccines Introduction
11.8.4 Novartis AG Revenue in Recombinant Vaccines Business (2020-2025)
11.8.5 Novartis AG Recent Development
11.9 Bharat Biotech
11.9.1 Bharat Biotech Company Details
11.9.2 Bharat Biotech Business Overview
11.9.3 Bharat Biotech Recombinant Vaccines Introduction
11.9.4 Bharat Biotech Revenue in Recombinant Vaccines Business (2020-2025)
11.9.5 Bharat Biotech Recent Development
11.10 AstraZeneca Plc.
11.10.1 AstraZeneca Plc. Company Details
11.10.2 AstraZeneca Plc. Business Overview
11.10.3 AstraZeneca Plc. Recombinant Vaccines Introduction
11.10.4 AstraZeneca Plc. Revenue in Recombinant Vaccines Business (2020-2025)
11.10.5 AstraZeneca Plc. Recent Development
11.11 Johnson & Johnson
11.11.1 Johnson & Johnson Company Details
11.11.2 Johnson & Johnson Business Overview
11.11.3 Johnson & Johnson Recombinant Vaccines Introduction
11.11.4 Johnson & Johnson Revenue in Recombinant Vaccines Business (2020-2025)
11.11.5 Johnson & Johnson Recent Development
11.12 Emergent BioSolutions Inc
11.12.1 Emergent BioSolutions Inc Company Details
11.12.2 Emergent BioSolutions Inc Business Overview
11.12.3 Emergent BioSolutions Inc Recombinant Vaccines Introduction
11.12.4 Emergent BioSolutions Inc Revenue in Recombinant Vaccines Business (2020-2025)
11.12.5 Emergent BioSolutions Inc Recent Development
11.13 Novavax, Inc
11.13.1 Novavax, Inc Company Details
11.13.2 Novavax, Inc Business Overview
11.13.3 Novavax, Inc Recombinant Vaccines Introduction
11.13.4 Novavax, Inc Revenue in Recombinant Vaccines Business (2020-2025)
11.13.5 Novavax, Inc Recent Development
11.14 Serum Institute of India Pvt. Ltd
11.14.1 Serum Institute of India Pvt. Ltd Company Details
11.14.2 Serum Institute of India Pvt. Ltd Business Overview
11.14.3 Serum Institute of India Pvt. Ltd Recombinant Vaccines Introduction
11.14.4 Serum Institute of India Pvt. Ltd Revenue in Recombinant Vaccines Business (2020-2025)
11.14.5 Serum Institute of India Pvt. Ltd Recent Development
11.15 Dynavax Technologies Corporation
11.15.1 Dynavax Technologies Corporation Company Details
11.15.2 Dynavax Technologies Corporation Business Overview
11.15.3 Dynavax Technologies Corporation Recombinant Vaccines Introduction
11.15.4 Dynavax Technologies Corporation Revenue in Recombinant Vaccines Business (2020-2025)
11.15.5 Dynavax Technologies Corporation Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Recombinant Vaccines Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Subunit Recombinant Vaccines
Table 3. Key Players of Attenuated Recombinant Vaccines
Table 4. Key Players of Vector Recombinant Vaccines
Table 5. Global Recombinant Vaccines Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Recombinant Vaccines Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Recombinant Vaccines Market Size by Region (2020-2025) & (US$ Million)
Table 8. Global Recombinant Vaccines Market Share by Region (2020-2025)
Table 9. Global Recombinant Vaccines Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 10. Global Recombinant Vaccines Market Share by Region (2026-2031)
Table 11. Recombinant Vaccines Market Trends
Table 12. Recombinant Vaccines Market Drivers
Table 13. Recombinant Vaccines Market Challenges
Table 14. Recombinant Vaccines Market Restraints
Table 15. Global Recombinant Vaccines Revenue by Players (2020-2025) & (US$ Million)
Table 16. Global Recombinant Vaccines Market Share by Players (2020-2025)
Table 17. Global Top Recombinant Vaccines Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Vaccines as of 2024)
Table 18. Ranking of Global Top Recombinant Vaccines Companies by Revenue (US$ Million) in 2024
Table 19. Global 5 Largest Players Market Share by Recombinant Vaccines Revenue (CR5 and HHI) & (2020-2025)
Table 20. Global Key Players of Recombinant Vaccines, Headquarters and Area Served
Table 21. Global Key Players of Recombinant Vaccines, Product and Application
Table 22. Global Key Players of Recombinant Vaccines, Date of Enter into This Industry
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Recombinant Vaccines Market Size by Type (2020-2025) & (US$ Million)
Table 25. Global Recombinant Vaccines Revenue Market Share by Type (2020-2025)
Table 26. Global Recombinant Vaccines Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 27. Global Recombinant Vaccines Revenue Market Share by Type (2026-2031)
Table 28. Global Recombinant Vaccines Market Size by Application (2020-2025) & (US$ Million)
Table 29. Global Recombinant Vaccines Revenue Market Share by Application (2020-2025)
Table 30. Global Recombinant Vaccines Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 31. Global Recombinant Vaccines Revenue Market Share by Application (2026-2031)
Table 32. North America Recombinant Vaccines Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 33. North America Recombinant Vaccines Market Size by Country (2020-2025) & (US$ Million)
Table 34. North America Recombinant Vaccines Market Size by Country (2026-2031) & (US$ Million)
Table 35. Europe Recombinant Vaccines Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 36. Europe Recombinant Vaccines Market Size by Country (2020-2025) & (US$ Million)
Table 37. Europe Recombinant Vaccines Market Size by Country (2026-2031) & (US$ Million)
Table 38. Asia-Pacific Recombinant Vaccines Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 39. Asia-Pacific Recombinant Vaccines Market Size by Region (2020-2025) & (US$ Million)
Table 40. Asia-Pacific Recombinant Vaccines Market Size by Region (2026-2031) & (US$ Million)
Table 41. Latin America Recombinant Vaccines Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 42. Latin America Recombinant Vaccines Market Size by Country (2020-2025) & (US$ Million)
Table 43. Latin America Recombinant Vaccines Market Size by Country (2026-2031) & (US$ Million)
Table 44. Middle East & Africa Recombinant Vaccines Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 45. Middle East & Africa Recombinant Vaccines Market Size by Country (2020-2025) & (US$ Million)
Table 46. Middle East & Africa Recombinant Vaccines Market Size by Country (2026-2031) & (US$ Million)
Table 47. Merck & Co., Inc Company Details
Table 48. Merck & Co., Inc Business Overview
Table 49. Merck & Co., Inc Recombinant Vaccines Product
Table 50. Merck & Co., Inc Revenue in Recombinant Vaccines Business (2020-2025) & (US$ Million)
Table 51. Merck & Co., Inc Recent Development
Table 52. Green Cross Corporation Company Details
Table 53. Green Cross Corporation Business Overview
Table 54. Green Cross Corporation Recombinant Vaccines Product
Table 55. Green Cross Corporation Revenue in Recombinant Vaccines Business (2020-2025) & (US$ Million)
Table 56. Green Cross Corporation Recent Development
Table 57. Pfizer Inc. Company Details
Table 58. Pfizer Inc. Business Overview
Table 59. Pfizer Inc. Recombinant Vaccines Product
Table 60. Pfizer Inc. Revenue in Recombinant Vaccines Business (2020-2025) & (US$ Million)
Table 61. Pfizer Inc. Recent Development
Table 62. Bayer AG Company Details
Table 63. Bayer AG Business Overview
Table 64. Bayer AG Recombinant Vaccines Product
Table 65. Bayer AG Revenue in Recombinant Vaccines Business (2020-2025) & (US$ Million)
Table 66. Bayer AG Recent Development
Table 67. Sanofi S A. Company Details
Table 68. Sanofi S A. Business Overview
Table 69. Sanofi S A. Recombinant Vaccines Product
Table 70. Sanofi S A. Revenue in Recombinant Vaccines Business (2020-2025) & (US$ Million)
Table 71. Sanofi S A. Recent Development
Table 72. Protein Science Corporation Company Details
Table 73. Protein Science Corporation Business Overview
Table 74. Protein Science Corporation Recombinant Vaccines Product
Table 75. Protein Science Corporation Revenue in Recombinant Vaccines Business (2020-2025) & (US$ Million)
Table 76. Protein Science Corporation Recent Development
Table 77. GlaxoSmithKline Plc. Company Details
Table 78. GlaxoSmithKline Plc. Business Overview
Table 79. GlaxoSmithKline Plc. Recombinant Vaccines Product
Table 80. GlaxoSmithKline Plc. Revenue in Recombinant Vaccines Business (2020-2025) & (US$ Million)
Table 81. GlaxoSmithKline Plc. Recent Development
Table 82. Novartis AG Company Details
Table 83. Novartis AG Business Overview
Table 84. Novartis AG Recombinant Vaccines Product
Table 85. Novartis AG Revenue in Recombinant Vaccines Business (2020-2025) & (US$ Million)
Table 86. Novartis AG Recent Development
Table 87. Bharat Biotech Company Details
Table 88. Bharat Biotech Business Overview
Table 89. Bharat Biotech Recombinant Vaccines Product
Table 90. Bharat Biotech Revenue in Recombinant Vaccines Business (2020-2025) & (US$ Million)
Table 91. Bharat Biotech Recent Development
Table 92. AstraZeneca Plc. Company Details
Table 93. AstraZeneca Plc. Business Overview
Table 94. AstraZeneca Plc. Recombinant Vaccines Product
Table 95. AstraZeneca Plc. Revenue in Recombinant Vaccines Business (2020-2025) & (US$ Million)
Table 96. AstraZeneca Plc. Recent Development
Table 97. Johnson & Johnson Company Details
Table 98. Johnson & Johnson Business Overview
Table 99. Johnson & Johnson Recombinant Vaccines Product
Table 100. Johnson & Johnson Revenue in Recombinant Vaccines Business (2020-2025) & (US$ Million)
Table 101. Johnson & Johnson Recent Development
Table 102. Emergent BioSolutions Inc Company Details
Table 103. Emergent BioSolutions Inc Business Overview
Table 104. Emergent BioSolutions Inc Recombinant Vaccines Product
Table 105. Emergent BioSolutions Inc Revenue in Recombinant Vaccines Business (2020-2025) & (US$ Million)
Table 106. Emergent BioSolutions Inc Recent Development
Table 107. Novavax, Inc Company Details
Table 108. Novavax, Inc Business Overview
Table 109. Novavax, Inc Recombinant Vaccines Product
Table 110. Novavax, Inc Revenue in Recombinant Vaccines Business (2020-2025) & (US$ Million)
Table 111. Novavax, Inc Recent Development
Table 112. Serum Institute of India Pvt. Ltd Company Details
Table 113. Serum Institute of India Pvt. Ltd Business Overview
Table 114. Serum Institute of India Pvt. Ltd Recombinant Vaccines Product
Table 115. Serum Institute of India Pvt. Ltd Revenue in Recombinant Vaccines Business (2020-2025) & (US$ Million)
Table 116. Serum Institute of India Pvt. Ltd Recent Development
Table 117. Dynavax Technologies Corporation Company Details
Table 118. Dynavax Technologies Corporation Business Overview
Table 119. Dynavax Technologies Corporation Recombinant Vaccines Product
Table 120. Dynavax Technologies Corporation Revenue in Recombinant Vaccines Business (2020-2025) & (US$ Million)
Table 121. Dynavax Technologies Corporation Recent Development
Table 122. Research Programs/Design for This Report
Table 123. Key Data Information from Secondary Sources
Table 124. Key Data Information from Primary Sources
Table 125. Authors List of This Report
List of Figures
Figure 1. Recombinant Vaccines Picture
Figure 2. Global Recombinant Vaccines Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Recombinant Vaccines Market Share by Type: 2024 VS 2031
Figure 4. Subunit Recombinant Vaccines Features
Figure 5. Attenuated Recombinant Vaccines Features
Figure 6. Vector Recombinant Vaccines Features
Figure 7. Global Recombinant Vaccines Market Size by Application (2020-2031) & (US$ Million)
Figure 8. Global Recombinant Vaccines Market Share by Application: 2024 VS 2031
Figure 9. Recombinant Human Vaccines Case Studies
Figure 10. Animal Recombinant Vaccines Case Studies
Figure 11. Recombinant Vaccines Report Years Considered
Figure 12. Global Recombinant Vaccines Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 13. Global Recombinant Vaccines Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Recombinant Vaccines Market Share by Region: 2024 VS 2031
Figure 15. Global Recombinant Vaccines Market Share by Players in 2024
Figure 16. Global Top Recombinant Vaccines Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Vaccines as of 2024)
Figure 17. The Top 10 and 5 Players Market Share by Recombinant Vaccines Revenue in 2024
Figure 18. North America Recombinant Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 19. North America Recombinant Vaccines Market Share by Country (2020-2031)
Figure 20. United States Recombinant Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. Canada Recombinant Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Europe Recombinant Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe Recombinant Vaccines Market Share by Country (2020-2031)
Figure 24. Germany Recombinant Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. France Recombinant Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. U.K. Recombinant Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Italy Recombinant Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Russia Recombinant Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Nordic Countries Recombinant Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Asia-Pacific Recombinant Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific Recombinant Vaccines Market Share by Region (2020-2031)
Figure 32. China Recombinant Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Japan Recombinant Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. South Korea Recombinant Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Southeast Asia Recombinant Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. India Recombinant Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Australia Recombinant Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Latin America Recombinant Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America Recombinant Vaccines Market Share by Country (2020-2031)
Figure 40. Mexico Recombinant Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Brazil Recombinant Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Middle East & Africa Recombinant Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa Recombinant Vaccines Market Share by Country (2020-2031)
Figure 44. Turkey Recombinant Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Saudi Arabia Recombinant Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. UAE Recombinant Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Merck & Co., Inc Revenue Growth Rate in Recombinant Vaccines Business (2020-2025)
Figure 48. Green Cross Corporation Revenue Growth Rate in Recombinant Vaccines Business (2020-2025)
Figure 49. Pfizer Inc. Revenue Growth Rate in Recombinant Vaccines Business (2020-2025)
Figure 50. Bayer AG Revenue Growth Rate in Recombinant Vaccines Business (2020-2025)
Figure 51. Sanofi S A. Revenue Growth Rate in Recombinant Vaccines Business (2020-2025)
Figure 52. Protein Science Corporation Revenue Growth Rate in Recombinant Vaccines Business (2020-2025)
Figure 53. GlaxoSmithKline Plc. Revenue Growth Rate in Recombinant Vaccines Business (2020-2025)
Figure 54. Novartis AG Revenue Growth Rate in Recombinant Vaccines Business (2020-2025)
Figure 55. Bharat Biotech Revenue Growth Rate in Recombinant Vaccines Business (2020-2025)
Figure 56. AstraZeneca Plc. Revenue Growth Rate in Recombinant Vaccines Business (2020-2025)
Figure 57. Johnson & Johnson Revenue Growth Rate in Recombinant Vaccines Business (2020-2025)
Figure 58. Emergent BioSolutions Inc Revenue Growth Rate in Recombinant Vaccines Business (2020-2025)
Figure 59. Novavax, Inc Revenue Growth Rate in Recombinant Vaccines Business (2020-2025)
Figure 60. Serum Institute of India Pvt. Ltd Revenue Growth Rate in Recombinant Vaccines Business (2020-2025)
Figure 61. Dynavax Technologies Corporation Revenue Growth Rate in Recombinant Vaccines Business (2020-2025)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
Table 1. Global Recombinant Vaccines Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Subunit Recombinant Vaccines
Table 3. Key Players of Attenuated Recombinant Vaccines
Table 4. Key Players of Vector Recombinant Vaccines
Table 5. Global Recombinant Vaccines Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Recombinant Vaccines Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Recombinant Vaccines Market Size by Region (2020-2025) & (US$ Million)
Table 8. Global Recombinant Vaccines Market Share by Region (2020-2025)
Table 9. Global Recombinant Vaccines Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 10. Global Recombinant Vaccines Market Share by Region (2026-2031)
Table 11. Recombinant Vaccines Market Trends
Table 12. Recombinant Vaccines Market Drivers
Table 13. Recombinant Vaccines Market Challenges
Table 14. Recombinant Vaccines Market Restraints
Table 15. Global Recombinant Vaccines Revenue by Players (2020-2025) & (US$ Million)
Table 16. Global Recombinant Vaccines Market Share by Players (2020-2025)
Table 17. Global Top Recombinant Vaccines Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Vaccines as of 2024)
Table 18. Ranking of Global Top Recombinant Vaccines Companies by Revenue (US$ Million) in 2024
Table 19. Global 5 Largest Players Market Share by Recombinant Vaccines Revenue (CR5 and HHI) & (2020-2025)
Table 20. Global Key Players of Recombinant Vaccines, Headquarters and Area Served
Table 21. Global Key Players of Recombinant Vaccines, Product and Application
Table 22. Global Key Players of Recombinant Vaccines, Date of Enter into This Industry
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Recombinant Vaccines Market Size by Type (2020-2025) & (US$ Million)
Table 25. Global Recombinant Vaccines Revenue Market Share by Type (2020-2025)
Table 26. Global Recombinant Vaccines Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 27. Global Recombinant Vaccines Revenue Market Share by Type (2026-2031)
Table 28. Global Recombinant Vaccines Market Size by Application (2020-2025) & (US$ Million)
Table 29. Global Recombinant Vaccines Revenue Market Share by Application (2020-2025)
Table 30. Global Recombinant Vaccines Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 31. Global Recombinant Vaccines Revenue Market Share by Application (2026-2031)
Table 32. North America Recombinant Vaccines Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 33. North America Recombinant Vaccines Market Size by Country (2020-2025) & (US$ Million)
Table 34. North America Recombinant Vaccines Market Size by Country (2026-2031) & (US$ Million)
Table 35. Europe Recombinant Vaccines Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 36. Europe Recombinant Vaccines Market Size by Country (2020-2025) & (US$ Million)
Table 37. Europe Recombinant Vaccines Market Size by Country (2026-2031) & (US$ Million)
Table 38. Asia-Pacific Recombinant Vaccines Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 39. Asia-Pacific Recombinant Vaccines Market Size by Region (2020-2025) & (US$ Million)
Table 40. Asia-Pacific Recombinant Vaccines Market Size by Region (2026-2031) & (US$ Million)
Table 41. Latin America Recombinant Vaccines Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 42. Latin America Recombinant Vaccines Market Size by Country (2020-2025) & (US$ Million)
Table 43. Latin America Recombinant Vaccines Market Size by Country (2026-2031) & (US$ Million)
Table 44. Middle East & Africa Recombinant Vaccines Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 45. Middle East & Africa Recombinant Vaccines Market Size by Country (2020-2025) & (US$ Million)
Table 46. Middle East & Africa Recombinant Vaccines Market Size by Country (2026-2031) & (US$ Million)
Table 47. Merck & Co., Inc Company Details
Table 48. Merck & Co., Inc Business Overview
Table 49. Merck & Co., Inc Recombinant Vaccines Product
Table 50. Merck & Co., Inc Revenue in Recombinant Vaccines Business (2020-2025) & (US$ Million)
Table 51. Merck & Co., Inc Recent Development
Table 52. Green Cross Corporation Company Details
Table 53. Green Cross Corporation Business Overview
Table 54. Green Cross Corporation Recombinant Vaccines Product
Table 55. Green Cross Corporation Revenue in Recombinant Vaccines Business (2020-2025) & (US$ Million)
Table 56. Green Cross Corporation Recent Development
Table 57. Pfizer Inc. Company Details
Table 58. Pfizer Inc. Business Overview
Table 59. Pfizer Inc. Recombinant Vaccines Product
Table 60. Pfizer Inc. Revenue in Recombinant Vaccines Business (2020-2025) & (US$ Million)
Table 61. Pfizer Inc. Recent Development
Table 62. Bayer AG Company Details
Table 63. Bayer AG Business Overview
Table 64. Bayer AG Recombinant Vaccines Product
Table 65. Bayer AG Revenue in Recombinant Vaccines Business (2020-2025) & (US$ Million)
Table 66. Bayer AG Recent Development
Table 67. Sanofi S A. Company Details
Table 68. Sanofi S A. Business Overview
Table 69. Sanofi S A. Recombinant Vaccines Product
Table 70. Sanofi S A. Revenue in Recombinant Vaccines Business (2020-2025) & (US$ Million)
Table 71. Sanofi S A. Recent Development
Table 72. Protein Science Corporation Company Details
Table 73. Protein Science Corporation Business Overview
Table 74. Protein Science Corporation Recombinant Vaccines Product
Table 75. Protein Science Corporation Revenue in Recombinant Vaccines Business (2020-2025) & (US$ Million)
Table 76. Protein Science Corporation Recent Development
Table 77. GlaxoSmithKline Plc. Company Details
Table 78. GlaxoSmithKline Plc. Business Overview
Table 79. GlaxoSmithKline Plc. Recombinant Vaccines Product
Table 80. GlaxoSmithKline Plc. Revenue in Recombinant Vaccines Business (2020-2025) & (US$ Million)
Table 81. GlaxoSmithKline Plc. Recent Development
Table 82. Novartis AG Company Details
Table 83. Novartis AG Business Overview
Table 84. Novartis AG Recombinant Vaccines Product
Table 85. Novartis AG Revenue in Recombinant Vaccines Business (2020-2025) & (US$ Million)
Table 86. Novartis AG Recent Development
Table 87. Bharat Biotech Company Details
Table 88. Bharat Biotech Business Overview
Table 89. Bharat Biotech Recombinant Vaccines Product
Table 90. Bharat Biotech Revenue in Recombinant Vaccines Business (2020-2025) & (US$ Million)
Table 91. Bharat Biotech Recent Development
Table 92. AstraZeneca Plc. Company Details
Table 93. AstraZeneca Plc. Business Overview
Table 94. AstraZeneca Plc. Recombinant Vaccines Product
Table 95. AstraZeneca Plc. Revenue in Recombinant Vaccines Business (2020-2025) & (US$ Million)
Table 96. AstraZeneca Plc. Recent Development
Table 97. Johnson & Johnson Company Details
Table 98. Johnson & Johnson Business Overview
Table 99. Johnson & Johnson Recombinant Vaccines Product
Table 100. Johnson & Johnson Revenue in Recombinant Vaccines Business (2020-2025) & (US$ Million)
Table 101. Johnson & Johnson Recent Development
Table 102. Emergent BioSolutions Inc Company Details
Table 103. Emergent BioSolutions Inc Business Overview
Table 104. Emergent BioSolutions Inc Recombinant Vaccines Product
Table 105. Emergent BioSolutions Inc Revenue in Recombinant Vaccines Business (2020-2025) & (US$ Million)
Table 106. Emergent BioSolutions Inc Recent Development
Table 107. Novavax, Inc Company Details
Table 108. Novavax, Inc Business Overview
Table 109. Novavax, Inc Recombinant Vaccines Product
Table 110. Novavax, Inc Revenue in Recombinant Vaccines Business (2020-2025) & (US$ Million)
Table 111. Novavax, Inc Recent Development
Table 112. Serum Institute of India Pvt. Ltd Company Details
Table 113. Serum Institute of India Pvt. Ltd Business Overview
Table 114. Serum Institute of India Pvt. Ltd Recombinant Vaccines Product
Table 115. Serum Institute of India Pvt. Ltd Revenue in Recombinant Vaccines Business (2020-2025) & (US$ Million)
Table 116. Serum Institute of India Pvt. Ltd Recent Development
Table 117. Dynavax Technologies Corporation Company Details
Table 118. Dynavax Technologies Corporation Business Overview
Table 119. Dynavax Technologies Corporation Recombinant Vaccines Product
Table 120. Dynavax Technologies Corporation Revenue in Recombinant Vaccines Business (2020-2025) & (US$ Million)
Table 121. Dynavax Technologies Corporation Recent Development
Table 122. Research Programs/Design for This Report
Table 123. Key Data Information from Secondary Sources
Table 124. Key Data Information from Primary Sources
Table 125. Authors List of This Report
List of Figures
Figure 1. Recombinant Vaccines Picture
Figure 2. Global Recombinant Vaccines Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Recombinant Vaccines Market Share by Type: 2024 VS 2031
Figure 4. Subunit Recombinant Vaccines Features
Figure 5. Attenuated Recombinant Vaccines Features
Figure 6. Vector Recombinant Vaccines Features
Figure 7. Global Recombinant Vaccines Market Size by Application (2020-2031) & (US$ Million)
Figure 8. Global Recombinant Vaccines Market Share by Application: 2024 VS 2031
Figure 9. Recombinant Human Vaccines Case Studies
Figure 10. Animal Recombinant Vaccines Case Studies
Figure 11. Recombinant Vaccines Report Years Considered
Figure 12. Global Recombinant Vaccines Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 13. Global Recombinant Vaccines Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Recombinant Vaccines Market Share by Region: 2024 VS 2031
Figure 15. Global Recombinant Vaccines Market Share by Players in 2024
Figure 16. Global Top Recombinant Vaccines Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Vaccines as of 2024)
Figure 17. The Top 10 and 5 Players Market Share by Recombinant Vaccines Revenue in 2024
Figure 18. North America Recombinant Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 19. North America Recombinant Vaccines Market Share by Country (2020-2031)
Figure 20. United States Recombinant Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. Canada Recombinant Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Europe Recombinant Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe Recombinant Vaccines Market Share by Country (2020-2031)
Figure 24. Germany Recombinant Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. France Recombinant Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. U.K. Recombinant Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Italy Recombinant Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Russia Recombinant Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Nordic Countries Recombinant Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Asia-Pacific Recombinant Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific Recombinant Vaccines Market Share by Region (2020-2031)
Figure 32. China Recombinant Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Japan Recombinant Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. South Korea Recombinant Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Southeast Asia Recombinant Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. India Recombinant Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Australia Recombinant Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Latin America Recombinant Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America Recombinant Vaccines Market Share by Country (2020-2031)
Figure 40. Mexico Recombinant Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Brazil Recombinant Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Middle East & Africa Recombinant Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa Recombinant Vaccines Market Share by Country (2020-2031)
Figure 44. Turkey Recombinant Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Saudi Arabia Recombinant Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. UAE Recombinant Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Merck & Co., Inc Revenue Growth Rate in Recombinant Vaccines Business (2020-2025)
Figure 48. Green Cross Corporation Revenue Growth Rate in Recombinant Vaccines Business (2020-2025)
Figure 49. Pfizer Inc. Revenue Growth Rate in Recombinant Vaccines Business (2020-2025)
Figure 50. Bayer AG Revenue Growth Rate in Recombinant Vaccines Business (2020-2025)
Figure 51. Sanofi S A. Revenue Growth Rate in Recombinant Vaccines Business (2020-2025)
Figure 52. Protein Science Corporation Revenue Growth Rate in Recombinant Vaccines Business (2020-2025)
Figure 53. GlaxoSmithKline Plc. Revenue Growth Rate in Recombinant Vaccines Business (2020-2025)
Figure 54. Novartis AG Revenue Growth Rate in Recombinant Vaccines Business (2020-2025)
Figure 55. Bharat Biotech Revenue Growth Rate in Recombinant Vaccines Business (2020-2025)
Figure 56. AstraZeneca Plc. Revenue Growth Rate in Recombinant Vaccines Business (2020-2025)
Figure 57. Johnson & Johnson Revenue Growth Rate in Recombinant Vaccines Business (2020-2025)
Figure 58. Emergent BioSolutions Inc Revenue Growth Rate in Recombinant Vaccines Business (2020-2025)
Figure 59. Novavax, Inc Revenue Growth Rate in Recombinant Vaccines Business (2020-2025)
Figure 60. Serum Institute of India Pvt. Ltd Revenue Growth Rate in Recombinant Vaccines Business (2020-2025)
Figure 61. Dynavax Technologies Corporation Revenue Growth Rate in Recombinant Vaccines Business (2020-2025)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Outdoor Shed Market Research Report 2025
Sep 09, 25
Global Residential Outdoor Cabinet Market Research Report 2025
Sep 09, 25
Global Outdoor Storage Cabinet Market Research Report 2025
Sep 09, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232